Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center
- PMID: 21898340
- DOI: 10.1002/art.30574
Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center
Abstract
Objective: To evaluate the symptomatic effects of highly purified chondroitin 4 and chondroitin 6 sulfate (CS) therapy in patients with osteoarthritis (OA) of the hand.
Methods: This investigator-initiated, single-center, randomized, double-blind, placebo-controlled clinical trial included 162 symptomatic patients with radiographic evidence of hand OA (American College of Rheumatology criteria). Inclusion criteria included patient's assessment of global spontaneous hand pain of at least 40 mm on a 0-100-mm visual analog scale (VAS) and functional impairment of at least 6 (0-30 scale) on the Functional Index for Hand OA (FIHOA) in the most symptomatic hand. Patients received either 800 mg of CS (n = 80 patients) or placebo (n = 82 patients) once daily for 6 months and were analyzed in an intent-to-treat approach. The two primary outcomes were the change in the patient's assessment of global spontaneous hand pain and in hand function (by FIHOA score) from baseline to month 6. Secondary outcomes were improvement in grip strength, duration of morning stiffness, acetaminophen consumption, and the investigator's global impression of treatment efficacy.
Results: There was a significantly more pronounced decrease in the patient's global assessment of hand pain in the CS group than in the placebo group (difference VAS scores -8.7 mm; P = 0.016). Hand function improved significantly more in the CS group than in the placebo group (difference in FIHOA scores -2.14; P = 0.008). There was a statistically significant between-group difference in favor of CS for the duration of morning stiffness and for the investigator's global impression of treatment efficacy. Changes in grip strength, acetaminophen consumption, and safety end points were not significantly different between the two groups.
Conclusion: This study demonstrates that CS improves hand pain and function in patients with symptomatic OA of the hand and shows a good safety profile.
Trial registration: ClinicalTrials.gov NCT00291499.
Copyright © 2011 by the American College of Rheumatology.
Comment in
-
In people with hand osteoarthritis, chondroitin sulphate therapy for 6 months improves pain and function compared with placebo.Evid Based Med. 2012 Oct;17(5):152-3. doi: 10.1136/ebmed-2011-100515. Epub 2012 Apr 5. Evid Based Med. 2012. PMID: 22491153 No abstract available.
Similar articles
-
Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Arthritis Rheumatol. 2017 Jan;69(1):77-85. doi: 10.1002/art.39819. Arthritis Rheumatol. 2017. PMID: 27477804 Clinical Trial.
-
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial.Trials. 2014 Oct 27;15:412. doi: 10.1186/1745-6215-15-412. Trials. 2014. PMID: 25348033 Free PMC article. Clinical Trial.
-
Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study.J Rheumatol. 2001 Jan;28(1):173-81. J Rheumatol. 2001. PMID: 11196521 Clinical Trial.
-
Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate.Rheum Dis Clin North Am. 1999 May;25(2):379-95. doi: 10.1016/s0889-857x(05)70074-0. Rheum Dis Clin North Am. 1999. PMID: 10356424 Review.
-
Glucosamine and chondroitin sulfate treatment of hand osteoarthritis.J Hand Surg Am. 2013 Aug;38(8):1638-40. doi: 10.1016/j.jhsa.2013.05.017. J Hand Surg Am. 2013. PMID: 23890502 Review. No abstract available.
Cited by
-
Report of similar placebo response in one internet versus onsite randomised controlled trials from the literature.Osteoarthr Cartil Open. 2024 Apr 27;6(2):100474. doi: 10.1016/j.ocarto.2024.100474. eCollection 2024 Jun. Osteoarthr Cartil Open. 2024. PMID: 38737983 Free PMC article.
-
Systematic review and network meta-analysis on the efficacy and safety of parmacotherapy for hand osteoarthritis.PLoS One. 2024 May 9;19(5):e0298774. doi: 10.1371/journal.pone.0298774. eCollection 2024. PLoS One. 2024. PMID: 38722915 Free PMC article.
-
Cloning and Characterization of a Novel N-Acetyl-D-galactosamine-4-O-sulfate Sulfatase, SulA1, from a Marine Arthrobacter Strain.Mar Drugs. 2024 Feb 23;22(3):104. doi: 10.3390/md22030104. Mar Drugs. 2024. PMID: 38535445 Free PMC article.
-
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis.Ther Adv Musculoskelet Dis. 2023 Mar 14;15:1759720X231158618. doi: 10.1177/1759720X231158618. eCollection 2023. Ther Adv Musculoskelet Dis. 2023. PMID: 36937821 Free PMC article. Review.
-
Soluble and EV-Associated Diagnostic and Prognostic Biomarkers in Knee Osteoarthritis Pathology and Detection.Life (Basel). 2023 Jan 27;13(2):342. doi: 10.3390/life13020342. Life (Basel). 2023. PMID: 36836699 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical